Realtime | Geld | Brief | Zeit |
---|---|---|---|
7,050 | 7,150 | 09:09 | |
7,050 | 7,150 | 08:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
---|---|---|---|---|
25.06. | Amneal Pharmaceuticals LLC: Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences | 90 | GlobeNewswire (Europe) | |
12.06. | Amneal Pharma Gets FDA Approval For Prednisolone Acetate Ophthalmic Suspension | - | RTTNews | |
12.06. | Amneal Pharmaceuticals LLC: Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension | 140 | GlobeNewswire (Europe) | |
10.06. | Amneal Pharmaceuticals bei Goldman Sachs Konferenz: Strategische Wachstumsvision | 5 | Investing.com Deutsch | |
06.06. | Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space | 20 | Seeking Alpha | |
06.06. | Goldman Sachs stuft Amneal Pharmaceuticals-Aktie mit neutraler Bewertung ein | 6 | Investing.com Deutsch | |
06.06. | Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating | 2 | Investing.com | |
05.06. | Amneal recalls 3 lots of a generic antibiotic after black spots found on tablets | 1 | FiercePharma | |
AMNEAL PHARMACEUTICALS Aktie jetzt für 0€ handeln | ||||
04.06. | Amneal recalls oral antibiotic due to bacterial contamination | 1 | Seeking Alpha | |
21.05. | DelveInsight Business Research, LLP: Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight | 341 | PR Newswire | |
16.05. | FDA approves Amneal's DHE migraine/cluster headache autoinjector | 2 | Pharmaceutical Technology | |
15.05. | Amneal gets U.S. FDA nod for Brekiya as a migraine treatment | 1 | Seeking Alpha | |
15.05. | US FDA approves Amneal's self-administered migraine treatment | 1 | Reuters | |
15.05. | Amneal Pharmaceuticals: FDA Approves Brekiya Injection | 2 | RTTNews | |
15.05. | Amneal erhält FDA-Zulassung für Brekiya-Autoinjektor zur Migränebehandlung | 6 | Investing.com Deutsch | |
15.05. | Amneal Pharmaceuticals LLC: Amneal Receives U.S. FDA Approval for Brekiya (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults | 184 | GlobeNewswire (Europe) | |
08.05. | Amneal bolsters US manufacturing capacity with Apiject collaboration deal | 2 | FiercePharma | |
07.05. | Amneal Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | |
02.05. | Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed | 3 | Benzinga.com | |
02.05. | Amneal targets $3B-$3.1B in 2025 revenue with strong growth drivers | 1 | Seeking Alpha |